

CLINICAL RESEARCH

Person-in-charge: V. Lodolini

Location: S. Anna Hospital and MTA

5 research assistants

The unit is constituted by 5 experts in clinical research, all graduated at the School of Clinical Researchers and Epidemiologists. The unit is responsible for all the bureaucratic procedures of clinical trials, organisation of the follow-up visits, contacts with industries, etc. Beside these standard activities, the unit is also actively involved in the planning, conduction, and analysis (together with the involved cardiologists) the **spontaneous** clinical trials produced by the cardiovascular centre [*Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia study (PRODIGY)*; *Functional versus Culprit-only Revascularization in Elderly Patients with Myocardial Infarction and Multivessel Disease trial (FIRE)*; *Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI (MULTISTRATEGY)*; *Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance (13T2R)*; *Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates (ZEUS)*; *Long-term Outcome of Deferred Lesion Based on FFR (HALE-BOPP)*; *Effectiveness of an early, tailored, Physical activity Intervention in ELderly patients with myocardial INfarction (PiPELINE)*; *Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)*; *Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes (SCAP)*; *Frailty in Elderly Patients Receiving Cardiac Interventional Procedures (FRASER)*; *ComparisoN of ticAgrelor vs. Clopidogrel in endoTHelial Function of COPD patieNts (NATHAN NEVER)*; *Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings (BATMAN)*; *Physical Activity Intervention for Patients With Reduced Physical Performance After Acute Coronary Syndrome (HULK)*; *Nutraceutical in Cardiovascular Primary Prevention(NIRVANA)*; *Scaffold in Emilia Romagna and in the MAGIC Network (SHERPA-MAGIC)*; *Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison(UNDERDOGS)*; *Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system: a two-centre prospective comparison (WOLFIE)*; *Safety and Feasibility of Transradial Mini-invasive Balloon Aortic Valvuloplasty (SOFTLY)*; *Angio-Based Fractional Flow Reserve to Predict Adverse Events After Stent Implantation (HAWKEYE)*; *Safety and Feasibility of Transradial Mini-invasive Balloon Aortic Valvuloplasty-II (SOFTLY-II)*; *Angio-based Quantitative Flow Ratio Virtual PCI Versus Conventional Angio-guided PCI in the Achievement of an Optimal Post-PCI QFR”(AQVA)*; *(Gauging Active Modalities of Error Detection and Signaling Obtained by Neural Interfaces in the Cathlab: The GAME-ON Study”(GAME-ON)]*.